Genes influence when babies walk, a later start may not signal a problem
The age at which babies learn to walk is strongly influenced by their genes, researchers have found, as they urged parents not to worry that they have done "something wrong."
Scientists analysed the genetic information of more than 70,000 babies and identified 11 genetic markers that influence when youngsters take their first steps.
The team, from the universities of Surrey and Essex, suggested genetics accounts for about a quarter of the differences in when children begin to walk. The findings were published in the journal Nature Human Behaviour.
"Most babies take their first step sometime between ages eight months and 24 months, so it is a wide window in which this exciting milestone happens," Professor Angelica Ronald, senior researcher on the study from the University of Surrey, said.
"It is a big moment for both parents and baby; it symbolises a new phase in a child's life," she said.
"While parents should still see their GP if they are concerned, a slightly later start is not always a sign of problems. There is a lot of variety in when children take their first step on their own."
Dr Anna Gui, who worked on the study, added: "Until now, we didn't understand what causes the wide differences between children in when they take their first step."
"Parents might often worry that walking early or late is a bad sign or that they have done something wrong. We see that genetics play a considerable role in influencing the timing of this milestone."
The study found that those genes influencing when children take their first steps are partly the same genetic factors that influence brain development.
There is also a relationship between later onset of walking and genes that are involved in higher educational attainment.
Walking later, but within the typical range, was further linked genetically with less chance of developing ADHD, the research suggested. – dpa
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 days ago
- Malaysian Reserve
British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)
TORONTO, July 23, 2025 /CNW/ – Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British Columbia1 PharmaCare formulary and First Nations Health Authority (FNHA) Pharmacy Benefit. With provincial funding in place in British Columbia, FOQUEST® is now reimbursed from coast to coast on all provincial drug plans across Canada. 'Public funding in British Columbia ensures equitable access to ADHD treatments in BC,' said Juanita Beaudry, Executive Director of the Centre for ADHD Awareness (CADDAC) 'This latest approval now provides access across Canada to another treatment option for patients.' British Columbia now joins Alberta2, Saskatchewan3, Manitoba4, Ontario5, Quebec6, Atlantic Canada7,8,9,10, the Non-Insured Health Benefit Plan11 and Correctional Service Canada in providing public formulary coverage for FOQUEST® for the treatment of ADHD in patients aged six years and older. 'Elvium Life Sciences is very pleased that British Columbia has now included Foquest on the BC PharmaCare Formulary to give physicians an additional choice for their ADHD patients who require public coverage,' said Jodan Ratz, Country Medical Director at Elvium Life Sciences. 'We thank the province for its decision which now means that all ADHD patients aged six years of age and older have equivalent access to Foquest should this be the right treatment for them.' See the full Canadian Product Monograph for FOQUEST®12 The Product Monograph for FOQUEST® contains a Serious Warning and Precaution for drug dependence, emphasizing that abuse of FOQUEST® can lead to dependence. Healthcare professionals should assess the risk of abuse prior to prescribing FOQUEST®, including in patients with a history of drug dependence or alcoholism, and monitor for signs of abuse and dependence while patients are on therapy. FOQUEST® is a once-daily, long-acting methylphenidate controlled-release capsule for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients greater than or equal to six years of age. The maximum daily dose of FOQUEST® for children and adolescents (6 to <18 years old) is 70mg, and the maximum daily dose for adults (≥18 years old) is 100 mg. Adverse events observed with FOQUEST® treatment mainly reflect side effects commonly associated with methylphenidate use. Very common adverse events reported by patients treated with FOQUEST® were headache, insomnia, decreased appetite and abdominal pain. Most of the events were mild to moderate in severity. About Elvium Life Sciences Elvium Life Sciences is an independent associated company of Purdue Pharma (Canada), that focuses on specialty pharmaceutical products committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) and products for ophthalmology. For more information, please visit FOQUEST® is a registered trademark of Purdue Pharma and is used under licence. References: 1. Available at: Accessed July 23, 2025 2. Available at: Accessed July 18, 2025 3. Available at: Accessed July 18, 2025 4. Available at: Accessed July 18, 2025 5. Available at: Accessed July 18, 2025 6. Available at: Accessed July 18, 2025 7. Available at: Accessed July 18, 2025 8. Available at: Accessed July 18, 2025 9. Available at: Accessed July 18, 2025 10. Available at: Accessed July 18, 2025 11. Available at: Accessed July 18, 2025. 12. Available at:
The Sun
3 days ago
- The Sun
A digital revolution transforms early assessment
WHEN Shun Matsuzuka was diagnosed as dyslexic at the age of 19, he was pursuing his foundation year at art school in the UK. It came as a total shock to him. As a child he enjoyed learning, but could not quite understand why his grades did not reflect his efforts or his curiousity in learning. 'That discovery at age 19 proved significant, as it helped me understand that my challenges were not due to lack of ability but rather a different way of processing information. It changed how I saw myself and later how I supported others facing similar struggles,' said Shun, who made the decision to move to Malaysia in 2017. He had worked as creative director for a global advertising agency in Japan. It was also a pivotal moment for Shun when he became a father. He preferred his daughter to grow up in a diverse environment, which Malaysia offered, due to its multicultural identity and culture. When his daughter turned 3 years, Shun received a government issued notice from Japan for a standardised developmental check-up in Japan for her. This he then realised was the missing gap in Malaysia, where there was no systematic developmental screening for children in the crucial ages of 3 to 5 years. Why develop a digital tool for assessment? 'After I became a parent, I was determined to build a tool that would help other children like me – before they start falling behind. That determination led to the creation of TOY8, which later when I introduced the screening aspect became known as TOY8 screening,' said Shun, who teamed up with a former Nintendo game director to co-design the app. The digital screening and intervention tool was also built in collaboration with Sunway University, University of Malaya and the Clinical Research Centre (CRC) of Ministry of Health (MOH). Dato' Dr Amar-Singh HSS, Consultant Pediatrician and child disability advocate said, 'Most Malaysian children receive surveillance and screening for developmental disabilities until the age of 18 months, linked to the Ministry of Health's (MOH) primary vaccination programme. Some may opt out to see private pediatricians. 'However, from the age of 2 to 6 years, most children do not receive any routine surveillance or screening. 'Developmental surveillance is also expensive in the private sector and limited. Hence important developmental disabilities such as Autism Spectrum Disorder, intellectual disabilities, attention deficit disorder (ADHD) and other specific learning disabilities, such as dyslexia are not identified. As a result, many children enter school, unable to face the academic challenges. For 2024, MOE reported that 122,000 year one students, which represents 24% of children for that age, lacked the essential skills of reading, writing and counting,' said Dr Amar-Singh. Today TOY8 screening provides parents with an invaluable opportunity to have their child screened; using this AI-powered digital screening tool in preschools so as to identify the children with learning disabilities early. TOY8 is revolutionary due to the time taken to screen the child, in total twenty minutes and the child-centred design and playful interaction is highly engaging for young children to use. Implementation of the TOY8 screening tool The developmental TOY8 screening project has been successfully introduced both in Sarawak and Selangor. The Sarawak state government offered TOY8 the opportunity to pilot the digital screening tool in preschools. In 2024, Shun launched the first pilot programme in Sarawak with 301 children. More than 30 children were identified as needing developmental support. 'We worked closely with local educators and health professionals to provide targeted interventions for each child. In 2025, the programme is expanding to reach 600 children across the state,' said Shun. In Selangor, the system is being spearheaded through organisations such as KEMAS, the community development department, an agency which manages preschools and the Selangor Children's Heritage Foundation, also referred to as Yayasan Warisan Anak Selangor (YAWAS). TOY8 is now preparing to present this Sarawak based model as a regional policy proposal at the 2025 ASEAN Business Summit, to be held in October this year and hosted by Malaysia. 'What began as a local effort has evolved into a globally recognised initiative. Sarawak's model is now seen as a towering initiative of how data and digital innovation can enable inclusive education to function as a full eco-system –integrating health, education and family support,' added Shun.
Sinar Daily
5 days ago
- Sinar Daily
Scientists find oldest trace of plague bacterium from 5,500 years ago
The earliest evidence of zoonotic diseases - illnesses transmitted from animals to humans - dates back to about 6,500 years ago and became more widespread about 1,500 years later. 20 Jul 2025 08:00pm A computer screen shows a human skull in a laboratory. (Photo by Roland DE COURSON / AFP) COPENHAGEN - A large-scale study of human disease dating back 37,000 years of harmful bacteria, viruses, and parasites that have afflicted humans for millennia has revealed that the first evidence of the plague bacterium occurred some 5,500 years ago, reported German Press Agency (dpa). The study mapped an entire catalogue of infectious diseases by analysing DNA of bones and teeth from 1,313 individuals who lived across Europe and Asia (Eurasia) from the Early Stone Age, around 12,500 years ago, to about 200 years ago, with the oldest sample dating as far back as 37,000 years ago. The study detected the world's oldest genetic trace of Yersinia pestis, the plague bacterium, in a sample dating back 5,500 years. The plague is estimated to have killed between one-quarter and one-half of Europe's population during the Middle Ages. - AFP file photo for illustration purpose only The researchers found that the earliest evidence of zoonotic diseases - illnesses transmitted from animals to humans - dates back to about 6,500 years ago and became more widespread about 1,500 years later. "We've long suspected that the transition to farming and animal husbandry opened the door to a new era of disease. Now, DNA shows us that it happened at least 6,500 years ago," said Professor Eske Willerslev, from the universities of Cambridge and Copenhagen. "These infections didn't just cause illness - they may have contributed to population collapse, migration, and genetic adaptation." The study detected the world's oldest genetic trace of Yersinia pestis, the plague bacterium, in a sample dating back 5,500 years. The plague is estimated to have killed between one-quarter and one-half of Europe's population during the Middle Ages. It also found traces of diphtheria going back 11,000 years, hepatitis B going back 9,800 years, and malaria 4,200 years ago. In total, researchers identified 214 known human pathogens in prehistoric humans from Eurasia. The study was published in the journal Nature on Wednesday. - BERNAMA-dpa
